A recent study presented at the American Academy of Neurology annual meeting looked at the outcomes of treating older adults with multiple sclerosis (MS) and signs of cancer with immune checkpoint inhibitors. The study found that 13 out of 38 patients treated with immune checkpoint inhibitors had partial or complete cancer remission. Overall, the treatment was safe and prevented relapse or disease progression in these patients. The study also found that most common tumors found in the study population were lung and melanoma. The researchers concluded that patients with MS can safely receive immune checkpoint inhibitor treatment for cancer.
Source link
Relapse, disease progression uncommon with immune checkpoint inhibitors in MS
